Chimerix (CMRX) Stock Price, News & Analysis

Company Overview

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $0.87 to $0.90
• 50-Day Range: $0.84 to $1.04
• 52-Week Range: $0.75 to $1.30
• Volume: 145,957 shs
• Average Volume: 352,736 shs
• Market Capitalization: $79.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Buy

Chimerix Stock Analysis - MarketRank™

Chimerix scored higher than 90% of companies evaluated by MarketBeat, and ranked 115th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Chimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Chimerix has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Chimerix are expected to decrease in the coming year, from ($0.99) to ($1.09) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chimerix is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chimerix is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Chimerix has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.90% of the float of Chimerix has been sold short.

Short Interest Ratio / Days to Cover

Chimerix has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chimerix has recently decreased by 12.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Chimerix does not currently pay a dividend.

Dividend Growth

Chimerix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -2.49

Percentage of Shares Shorted

1.90% of the float of Chimerix has been sold short.

Short Interest Ratio / Days to Cover

Chimerix has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chimerix has recently decreased by 12.64%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.83

News Sentiment

Chimerix has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Chimerix this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for CMRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Chimerix insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.10% of the stock of Chimerix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CMRX Stock Analysis - Frequently Asked Questions

How have CMRX shares performed this year?

Chimerix's stock was trading at $0.9625 at the beginning of 2024. Since then, CMRX shares have decreased by 8.6% and is now trading at $0.88.
View the best growth stocks for 2024 here.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) posted its quarterly earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, meeting the consensus estimate of ($0.23). The biopharmaceutical company earned $0.13 million during the quarter, compared to analyst estimates of $1.26 million.

Who are Chimerix's major shareholders?

Top institutional shareholders of Chimerix include Geode Capital Management LLC (0.94%), Connor Clark & Lunn Investment Management Ltd. (0.38%), Assenagon Asset Management S.A. (0.36%) and Valeo Financial Advisors LLC (0.09%). Insiders that own company stock include Michael T Andriole, David Jakeman, Michelle Laspaluto, Fred A Middleton and Robert J Meyer.
View institutional ownership trends.

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Chimerix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Chimerix investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), Pfizer (PFE) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CMRX
• CUSIP: N/A
• CIK: 1117480
• Web: www.chimerix.com
• Phone: (919) 806-1074
• Fax: 919-806-1146
• Employees: 72
• Year Founded: 2000

Price Target and Rating

• Average Stock Price Target: $8.50
• High Stock Price Target: $11.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +865.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-82,100,000.00
• Net Margins: N/A
• Pretax Margin: -52,574.85%
• Return on Equity: -50.78%
• Return on Assets: -44.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.33
• Quick Ratio: 6.33

Sales & Book Value

• Annual Sales: $320,000.00
• Price / Sales: 247.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.17 per share
• Price / Book: 0.41

Miscellaneous

• Outstanding Shares: 89,940,000
• Free Float: 78,154,000
• Market Cap: $79.15 million
• Optionable: Optionable
• Beta: 1.13